StockData
OKYO Pharma Ltd logo

OKYO Pharma Ltd (OKYO) stock

OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.10−0.00 (-0.45%)

Close on Nov 18, 2026Market cap $57.73MP/E –Yield –

OKYO Pharma r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $1.81M, down 19.7% from the year before. The highest annual figure on record is $8.24M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$1.81M-19.7%
FY2025Mar 31, 2025$2.25M-72.7%
FY2024Mar 31, 2024$8.24M+30.1%
FY2023Mar 31, 2023$6.34M+293.8%
FY2022Mar 31, 2022$1.61M+362.1%
FY2021Mar 31, 2021$348.35K-32.8%
FY2020Mar 31, 2020$518.10K–

More OKYO Pharma figures

See a number that looks wrong?